View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of th...

 PRESS RELEASE

JDE Peet’s share buyback periodic update August 18, 2025

JDE Peet’s share buyback periodic update August 18, 2025 PRESS RELEASEAmsterdam, August 18, 2025JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee company, today announced that it has repurchased 247,873 shares in the period from August 11, 2025 up to and including August 15, 2025.  The shares were repurchased at an average price of EUR 26.03 per share for a total consideration of EUR 6.5 million. These repurchases were made as part of the EUR 250 million share buyback programme . The total number of shares repurchased under this programme to date is 5,247,069 ordinary shar...

 PRESS RELEASE

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity. The accelerated approval is based...

 PRESS RELEASE

Hermès International : Shares and voting rights as of 31st July 2025

Hermès International : Shares and voting rights as of 31st July 2025 RELEASE Paris, August 12, 2025 INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES COMPRISING THE SHARE CAPITAL In accordance with the provisions of Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés Financiers (AMF), Hermès international publishes each month, before the 15th day of the following month, the total number of voting rights and the number of shares comprising the share capital if they have varied from...

 PRESS RELEASE

Hermès International : Actions et droits de vote au 31 juillet 2025

Hermès International : Actions et droits de vote au 31 juillet 2025 COMMUNIQUÉ Paris, le 12 août 2025 INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL Conformément aux dispositions de l’article L. 233-8 du Code de commerce et de l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers (AMF), Hermès international publie chaque mois, avant le 15 du mois suivant, le nombre total de droits de vote et le nombre d’actions composant le capital social s’ils ont varié par rapport à ceux publiés antérieurement.DateNombre d’actions c...

 PRESS RELEASE

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 12 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of th...

 PRESS RELEASE

JDE Peet’s share buyback periodic update August 11, 2025

JDE Peet’s share buyback periodic update August 11, 2025 PRESS RELEASEAmsterdam, August 11, 2025JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee company, today announced that it has repurchased 167,402 shares in the period from August 4, 2025 up to and including August 8, 2025.  The shares were repurchased at an average price of EUR 25.77 per share for a total consideration of EUR 4.3 million. These repurchases were made as part of the EUR 250 million share buyback programme . The total number of shares repurchased under this programme to date is 4,999,196 ordinary shares...

 PRESS RELEASE

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 8 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of the...

 PRESS RELEASE

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 7 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Martial Descoutures
  • Martial Descoutures
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch